Please access the Journal of Acquired Immune Deficiency Syndromes (JAIDS) Editorial Manager portal for manuscript submissions. Please follow all instructions and guidelines carefully to avoid delays and possible rejection. During submission, authors are given the option to submit papers to one of the following tracks: Basic Science, Clinical Science, Translational Research, Epidemiology, Implementation Science, Prevention Research, and Critical Review.
Submit a manuscript
In the changing landscape of HIV research JAIDS priorities are premised on attracting research submissions at the cutting edge that advance the field. Of particular interest are submissions aligned with the National Institutes of Health Office of AIDS Research high priority research areas (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html). As such the field is beyond descriptive analyses that redundantly identify challenges to achieving the overarching goal of HIV elimination and urge "urgent" intervention. Rather JAIDS is interested in studies that contribute new knowledge that fundamentally advances the field often engaging multidisciplinary strategies. Examples of priority research are basic studies targeting the biology of HIV transmission, immuno-pathogenesis, the role of the host microbiome and genetic factors including studies that integrate these techniques into clinical (e.g. biomarkers) and population research (e.g. molecular epidemiology). HIV cure research drives a research agenda with significant intersection with clinical and translational strategies to understand and eliminate persistent viral reservoirs and engage novel clinical and cohort strategies linked to basic laboratory application. Basic research extends beyond the laboratory to clinical and population settings and includes application of novel methods of behavioral research to gain fundamental insights to the mechanisms that drive barriers to uptake and adherence to treatment and preventative approaches to guide innovative implementation science interventions. Beyond descriptive studies are the application of methods to formally test interventions and their impact whether in classic randomized trials or evolving variations conducted at the population level. Priorities include evidence-based studies that document the impact of preventative strategies including therapeutic and biologic interventions and formal evaluation of strategies to extend these approaches to public health scale up. JAIDS has a strong commitment to publishing results of therapy trials and translational studies of emerging treatments with improved pharmacokinetics and toxicity profiles and their adaptation to clinical practice and extension to the global HIV treatment response. Linked to this goal are basic behavioral, population and implementation research studies to optimize achievement of the WHO 90-90-90 paradigm. Studies to advance the treatment and prevention of HIV-associated comorbidities (cancer, metabolic, neurologic, cardiovascular) and coinfections especially TB and Hepatitis C are of high interest to JAIDS. Basic and population research to gain fundamental insights concerning health disparities based on race, gender identity, and sexual practice and surrounding psycho-social and stigma barriers are also emphasis areas. JAIDS also capitalizes on the clear synergy across the boundaries of related viral infections particularly in the HCV and HBV research arena.
View the latest Instructions for Authors